FDA puts experimental T-cell treatment for ALS on fast track

The FDA granted fast-track designation to CK0803, an experimental T-cell therapy for ALS currently in Phase 1 clinical trials, to accelerate its development and review. CK0803 aims to reduce neuroinflammation by targeting regulatory T-cells without requiring donor matching, potentially slowing ALS progression.

This Wire brief sits within Fusion42's coverage of Biotech.